Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Yamaya (Yokohama city, Japan), E. Hagiwara (Yokohama city, Japan), T. Baba (Yokohama city, Japan), T. Iwasawa (Yokohama city, Japan), T. Ogura (Yokohama city, Japan). Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs. 2254

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Next generation of anti-inflammatory therapy for COPD? Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017 Year: 2017 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 The mechanisms of antiinflammatory effect of mucolytic therapy Source: International Congress 2014 – Predictors Year: 2014 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 ACE and sIL2-R predict lung function improvement in sarcoidosis during methotrexate therapy Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure Year: 2018 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Potential synergism of drugs with anti-viral and pulmonary oedema clearance activity may be advantageous for influenza patients Source: Annual Congress 2011 - Insight into mechanisms of respiratory infections Year: 2011 Monitoring anti-inflammatory treatments in IPF and related disorders Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments Year: 2004 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Can toxicities induced by antituberculosis drugs be better managed in diabetic patients? Source: Eur Respir J, 50 (1) 1700409; 10.1183/13993003.00409-2017 Year: 2017 Mucolytics and anti-inflammatory lung treatments Source: ERS course 2015 Year: 2015